Transgene (0OCQ) Stock Overview

A biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. More details

0OCQ fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 76.15% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

0OCQ Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Transgene SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for Transgene
Historical stock prices
Current Share Price	€0.75
52 Week High	€1.50
52 Week Low	€0.73
Beta	0.71
1 Month Change	-9.58%
3 Month Change	-0.27%
1 Year Change	-13.26%
3 Year Change	-61.06%
5 Year Change	-67.91%
Change since IPO	-92.90%

Recent updates

Shareholder Returns

	0OCQ	GB Biotechs	GB Market
7D	-2.1%	0.1%	-0.4%
1Y	-13.3%	21.7%	18.3%

Return vs Industry: 0OCQ underperformed the UK Biotechs industry which returned 22.8% over the past year.

Return vs Market: 0OCQ underperformed the UK Market which returned 17.5% over the past year.

Price Volatility

Is 0OCQ's price volatile compared to industry and market?
0OCQ volatility
0OCQ Average Weekly Movement	4.7%
Biotechs Industry Average Movement	8.0%
Market Average Movement	5.5%
10% most volatile stocks in GB Market	11.1%
10% least volatile stocks in GB Market	3.0%

Stable Share Price: 0OCQ has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0OCQ's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1979	145	Alessandro Riva	www.transgene.com

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial.

Transgene SA Fundamentals Summary

How do Transgene's earnings and revenue compare to its market cap?
0OCQ fundamental statistics
Market cap	€205.96m
Earnings (TTM)	-€37.52m
Revenue (TTM)	€7.21m

28.4x

P/S Ratio

-5.5x

P/E Ratio

Is 0OCQ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0OCQ income statement (TTM)
Revenue	€7.21m
Cost of Revenue	€33.90m
Gross Profit	-€26.69m
Other Expenses	€10.84m
Earnings	-€37.52m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Sep 24, 2026

Earnings per share (EPS)	-0.14
Gross Margin	-370.12%
Net Profit Margin	-520.44%
Debt/Equity Ratio	1.7%

How did 0OCQ perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/22 19:01
End of Day Share Price	2026/06/22 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Transgene SA is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Arsene Guekam	CIC Market Solutions (ESN)
Michael Thomas Cooper	Edison Investment Research
Martial Descoutures	ODDO BHF Corporate & Markets

Transgene (0OCQ) Stock Overview

Rewards

Risk Analysis

Transgene SA Competitors

Scancell Holdings

Bioventix

Oxford Biomedica

Genus

Price History & Performance

Recent News & Updates

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine

Less than half of directors are independent

Transgene SA Announces Board Appointments

Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer

Full year 2025 earnings released: €0.26 loss per share (vs €0.29 loss in FY 2024)

Transgene SA, Annual General Meeting, May 13, 2026

Recent updates

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine

Less than half of directors are independent

Transgene SA Announces Board Appointments

Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer

Full year 2025 earnings released: €0.26 loss per share (vs €0.29 loss in FY 2024)

Transgene SA, Annual General Meeting, May 13, 2026

New major risk - Revenue and earnings growth

Transgene SA to Report Q3, 2026 Results on Nov 09, 2026

Transgene SA Announces Board Appointments

Transgene Announces the Preprint Publication on Medrxiv of A Comprehensive Analysis of Both the Clinical and Translational Data from the Phase I/Ii Trial of Tg4050

New major risk - Shareholder dilution

New major risk - Share price stability

Transgene SA has completed a Follow-on Equity Offering in the amount of €144.262016 million.

New major risk - Negative shareholders equity

First half 2025 earnings released: €0.15 loss per share (vs €0.16 loss in 1H 2024)

Transgene SA Announces Board Changes

Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer

Transgene to Present 24-Month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, At Asco 2025

Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025

Transgene SA, Annual General Meeting, May 15, 2025

Transgene SA Appoints Simone Steiner as Chief Technical Officer

Full year 2024 earnings released: €0.29 loss per share (vs €0.22 loss in FY 2023)

New major risk - Shareholder dilution

Transgene SA to Report First Half, 2025 Results on Sep 16, 2025

New minor risk - Market cap size

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

Less than half of directors are independent

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

New minor risk - Shareholder dilution

Less than half of directors are independent

New major risk - Financial position

Full year 2023 earnings released: €0.22 loss per share (vs €0.33 loss in FY 2022)

Transgene SA Announces Chief Financial Officer Changes

Transgene SA, Annual General Meeting, May 15, 2024

First half 2023 earnings released: €0.16 loss per share (vs €0.15 loss in 1H 2022)

First half 2023 earnings released

New major risk - Financial position

BioInvent Ready for Combination Studies with BT-001

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Transgene SA Appoints Carol Stuckley as Independent Director

Full year 2022 earnings released: €0.33 loss per share (vs €0.21 loss in FY 2021)

Transgene Receives Approval to Start a Phase I Trial of TG6050

Transgene SA to Report First Half, 2023 Results on Sep 20, 2023

No longer forecast to breakeven

First half 2022 earnings released

No longer forecast to breakeven

No longer forecast to breakeven

First half 2021 earnings released

Transgene SA has completed a Follow-on Equity Offering in the amount of €34.1285 million.

Revenue misses expectations

Full year 2020 earnings released: €0.21 loss per share (vs €0.23 loss in FY 2019)

First half earnings released

Shareholder Returns

Price Volatility

About the Company

Transgene SA Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources